FcGBP and VCAM-1 are ponderable biomarkers for differential diagnosis of alcoholic liver cirrhosis

Abassa, Kodjo-Kunale; Xiao, Xiu-Ping; Zhou, Haoxiong; Wu, Xiaoying; Guo, Yi; Wu, Bin

doi:10.1016/j.drugalcdep.2022.109377

Cited by 8 publications

(6 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…NAFLD is a disease of liver parenchyma caused by excessive fat content in the liver cells due to genetic predisposition and insulin resistance. To some extent chronic hepatitis B and NAFLD are two separate diseases [ 17 , 18 ], they often appear in a combined form and have a more pronounced effect on each other, leading to liver fibrosis. The two diseases are often combined and have a significant impact on each other, leading to liver fibrosis, which can accelerate cirrhosis if the patient does not receive the relevant treatment in the first place.…”

Section: Discussionmentioning

confidence: 99%

A Meta-Analysis of How Nonalcoholic Fatty Liver Disease Affect Antiviral Treatment of Patients with e Antigen-Positive Chronic Hepatitis B

Chen

Liu

Han

et al. 2022

Emergency Medicine International

View full text Add to dashboard Cite

Background. Nonalcoholic fatty liver disease (NAFLD) and chronic hepatitis B (CHB) are both the most common underlying diseases leading to cirrhosis and hepatocellular carcinoma, and NAFLD and HBV infection are the first and second leading causes of chronic liver disease in China. However, there are still a lot of controversies about whether the combined presence of CHB and NAFLD will affect the course or outcome of liver disease together with HBV, and how the two affect each other. Objective. To investigate the effect of nonalcoholic fatty liver disease (NAFLD) on antiviral therapy in patients with chronic hepatitis B (CHB). Methods. Computer searches of databases such as PubMed, CNKI, VIP.com, and Wanfang Data Knowledge Service Platform were used. The time frame was from the creation of the database to June 2022. The search subject terms were hepatitis B, CHB, or NAFLD. The observation group consisted of patients with e antigen-positive CHB with NAFLD, and the control group consisted of patients with e-antigen + CHB. Extracts including title, name, date of publication, number of samples, antiviral drugs, and outcome indicators were used for Meta-analysis. Funnel plots were drawn to analyze literature bias. Results. Seven papers including 1348 patients with HBeAg + CHB (observation group: n = 547, control group: n = 801) were finally included. Results. Meta-analysis showed that CHB patients with NAFLD had lower efficacy than CHB patients after 48 weeks of antiviral treatment with nucleotide analogs, as measured by three outcome indicators HBV DNA conversion rate, ALT-normalization, and HBeAg conversion rate. Conclusion. NAFLD reduces the effect of antiviral therapy in CHB patients, and the clinicopathological features of patients with NAFLD combined with chronic hepatitis B are different from those of patients with chronic hepatitis B alone, so early diagnosis by liver histological examination should be actively performed and reasonable antiviral therapy should be administered.

show abstract

Section: Discussionmentioning

confidence: 99%

A Meta-Analysis of How Nonalcoholic Fatty Liver Disease Affect Antiviral Treatment of Patients with e Antigen-Positive Chronic Hepatitis B

Chen

Liu

Han

et al. 2022

Emergency Medicine International

View full text Add to dashboard Cite

show abstract

“…Nonetheless, we are using this system to carry out some research. Currently, a series of retrospective and prospective studies are being conducted using this DSCDS for liver cirrhosis, including follow-up studies on the therapeutic effect and prognosis of gastroesophageal variceal hemorrhage, prognostic predictions of liver cirrhosis based on multimodal data, the potential correlation between medical history, genetic and imaging features and liver cirrhosis [ 19 ], and large cohort studies on the characteristics, influencing factors and complications of liver cirrhosis [ 20 , 21 ]. We applied for a clinical trial to study the quantitative evaluation and reversible treatment of liver cirrhosis (registration number: ChiCTR1900023426).…”

Section: Resultsmentioning

confidence: 99%

Design and development of a disease-specific clinical database system to increase the availability of hospital data in China

Liu

Luo

et al. 2023

Health Inf Sci Syst

Self Cite

View full text Add to dashboard Cite

Purpose In order to meet restrictions and difficulties in the development of hospital medical informatization and clinical databases in China, in this study, a disease-specific clinical database system (DSCDS) was designed and built. It provides support for the full utilization of real world medical big data in clinical research and medical services for specific diseases. Methods The development of DSCDS involved (1) requirements analysis on precision medicine, medical big data, and clinical research; (2) design schematics and basic architecture; (3) standard datasets of specific diseases consisting of common data elements (CDEs); (4) collection and aggregation of specific disease data scattered in various medical business systems of the hospital; (5) governance and quality improvement of specific disease data; (6) data storage and computing; and (7) design of data application modules. Results A DSCDS for liver cirrhosis was created in the gastrointestinal department of a 3A grade hospital in China and had more than nine data application modules. Based on this DSCDS, a series of clinical studies are being carried out, such as retrospective or prospective cohorts, prognostic studies using multimodal data, and follow-up studies. Conclusion The development of the DSCDS for liver cirrhosis in this paper provides experience and reference for the design and development of DSCDSs for other specific diseases in China; it can even expand to the development of DSCDSs in other countries if they have the demand for DSCDS and the same or better medical informatization foundation. DSCDS has more accurate, standard, comprehensive, multimodal and usable data of specific diseases than the general clinical database system and clinical data repository (CDR) and provides a credible data foundation for medical research, clinical decision-making and improving the medical service quality of specific diseases.

show abstract

“…Our results showed a higher MUC2 expression in goblet cells and Paneth cells in cirrhosis compared to controls, like the alcohol-related mouse study mentioned above, which could be a compensatory mechanism. This was accompanied by lower FcGBP and SPDEF expression in advanced decompensated TI Paneth and goblet cells [ 33 , 34 ]. Both FcGBP and SPDEF are involved in the differentiation of goblet and Paneth cells.…”

Section: Discussionmentioning

confidence: 99%

Single nuclear RNA sequencing of terminal ileum in patients with cirrhosis demonstrates multi-faceted alterations in the intestinal barrier

Jiang,

Xu,

Fagan

et al. 2024

Cell Biosci

View full text Add to dashboard Cite

Patients with cirrhosis have intestinal barrier dysfunction but the role of the individual cell types in human small intestine is unclear. We performed single-nuclear RNA sequencing (snRNAseq) in the pinch biopsies of terminal ileum of four age-matched men [56 years, healthy control, compensated, early (ascites and lactulose use) and advanced decompensated cirrhosis (ascites and rifaximin use)]. Cell type proportions, differential gene expressions, cell-type specific pathway analysis using IPA, and cellular crosstalk dynamics were compared. Stem cells, enterocytes and Paneth cells were lowest in advanced decompensation. Immune cells like naive CD4 + T cells were lowest while ITGAE + cells were highest in advanced decompensation patients. MECOM had lowest expression in stem cells in advanced decompensation. Defensin and mucin sulfation gene (PAPSS2) which can stabilize the mucus barrier expression were lowest while IL1, IL6 and TNF-related genes were significantly upregulated in the enterocytes, goblet, and Paneth cells in decompensated subjects. IPA analysis showed higher inflammatory pathways in enterocytes, stem, goblet, and Paneth cells in decompensated patients. Cellular crosstalk analysis showed that desmosome, protease-activated receptors, and cadherin-catenin complex interactions were most perturbed in decompensated patients. In summary, the snRNAseq of the human terminal ileum in 4 subjects (1 control and three cirrhosis) identified multidimensional alteration in the intestinal barrier with lower stem cells and altered gene expression focused on inflammation, mucin sulfation and cell–cell interactions with cirrhosis decompensation.

show abstract

FcGBP and VCAM-1 are ponderable biomarkers for differential diagnosis of alcoholic liver cirrhosis

Cited by 8 publications

References 20 publications

A Meta-Analysis of How Nonalcoholic Fatty Liver Disease Affect Antiviral Treatment of Patients with e Antigen-Positive Chronic Hepatitis B

A Meta-Analysis of How Nonalcoholic Fatty Liver Disease Affect Antiviral Treatment of Patients with e Antigen-Positive Chronic Hepatitis B

Design and development of a disease-specific clinical database system to increase the availability of hospital data in China

Single nuclear RNA sequencing of terminal ileum in patients with cirrhosis demonstrates multi-faceted alterations in the intestinal barrier

Contact Info

Product

Resources

About